Start Date
March 31, 2011
Primary Completion Date
February 29, 2012
Study Completion Date
February 29, 2012
irinotecan, capecitabine, oxaliplatin (IXO) and bevacizumab
IXO plus bevacizumab regimen is given every 3 weeks (Q3W), in the following order: Bevacizumab (A): 7.5 mg/kg via IV infusion, day 1 Oxaliplatin (O): 100 mg/m2 via 2-hour IV infusion, day 1 Irinotecan (I): 160 mg/m2 via 1-hour IV infusion, day 1 Capecitabine (X): 950 mg/m2 twice daily PO, days 2 - 15
The Ottawa Hospital Cancer Center, Ottawa
Sunnybrook Health Sciences Centre, Toronto
University Health Network, Toronto
McGill University Health Centre, Montreal
Lead Sponsor
Collaborators (1)
Hoffmann-La Roche
INDUSTRY
Sanofi
INDUSTRY
Ottawa Hospital Research Institute
OTHER